RM
Insider
Robert Mashal
DirectorRobert Mashal (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Nuvation Bio Inc. (NUVB). Across 1 priced purchase filing, the average 21-session return was +20.3% from execution and +26.8% from disclosure (delay-adjusted; derived). The largest single filing was $118K of NUVB (25,000 sh × $4.73, as filed), executed Jun 9.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+20.3%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+26.8%
same 1 filings, from disclosure
Filings, ttm
1
1 buys · 0 sells
Median delay
2d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$118K
shares × price, as filed
Last traded
Jun 9
Filed Jun 11
Median ADV $43.2M across their filed names
Open performance→Volume by month
Buys $503K
Sells $0
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
1 filing
Sector per market data · by filing · past 12 months
Most traded names
NUVB
Nuvation Bio Inc.
NUVB · 3 buys · 0 sells
3 filings
Recent filings
NUVBPURCHASE
Nuvation Bio Inc.
View filing →
$118K25,000 sh × $4.73
Exec Jun 9
Filed Jun 11 · 8:02 PM ET NUVBPURCHASE Nuvation Bio Inc. View filing → $165K
98,900 sh × $1.67
Exec Apr 1 2025
Filed Apr 3 2025 · 5:30 PM ET NUVBPURCHASE Nuvation Bio Inc. View filing → $220K
99,981 sh × $2.20
Exec Oct 8 2024
Filed Oct 10 2024 · 5:30 PM ET